Last reviewed · How we verify
Mepivacaine plus Tramadol
At a glance
| Generic name | Mepivacaine plus Tramadol |
|---|---|
| Also known as | Tradol |
| Sponsor | Daniel Chavarría Bolaños |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Impact of Tramadol Addiction On Dental Anesthesia Success (PHASE4)
- Mepivacaine-Tramadol on the Success of Inferior Alveolar Nerve Block in Symptomatic Irreversible Pulpitis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mepivacaine plus Tramadol CI brief — competitive landscape report
- Mepivacaine plus Tramadol updates RSS · CI watch RSS
- Daniel Chavarría Bolaños portfolio CI